Format

Send to

Choose Destination
Eur Urol. 2016 Jun;69(6):988-91. doi: 10.1016/j.eururo.2015.09.026. Epub 2015 Oct 4.

Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study.

Author information

1
APHP, Urology Department, Henri Mondor Teaching Hospital, Créteil, France. Electronic address: rene.yiou@hmn.aphp.fr.
2
APHP, Department of Physiology, Henri Mondor Teaching Hospital, Créteil, France.
3
Etablissement Français du Sang, Unité d'Ingénierie et de thérapie cellulaire, Créteil, France.
4
APHP, CIC-P006, and CIC-BT 504, Henri Mondor Teaching Hospital, Créteil, France.
5
APHP, Anesthesiology Department, Henri Mondor Teaching Hospital, Créteil, France.
6
APHP, Urology Department, Henri Mondor Teaching Hospital, Créteil, France.
7
INSERM, U955, UPEC, Créteil, France.
8
APHP, Department of Public Health of Statistics, Henri Mondor Teaching Hospital, Créteil, France.

Abstract

Evidence from animal models replicating postradical prostatectomy erectile dysfunction (pRP-ED) suggests intracavernous injection of bone marrow-mononuclear cells (BM-MNCs) as a promising treatment approach for pRP-ED. We conducted a phase 1/2 pilot clinical trial of intracavernous autologous BM-MNC injection to treat pRP-ED (NCT01089387). Twelve patients with localized prostate cancer and vasculogenic pRP-ED refractory to maximal medical treatment were divided into four equal groups treated with escalating BM-MNC doses (2×10(7), 2×10(8), 1×10(9), 2×10(9)). Tolerance was the primary endpoint. Secondary endpoints were the effects on erectile function and penile vascularization at 6 mo, as assessed using the International Index of Erectile Function-15 and Erection Hardness Scale questionnaires, and color duplex Doppler ultrasound. We measured the peak systolic velocity in cavernous arteries and assessed endothelial function using the penile nitric oxide release test. No serious side effects occurred. At 6 mo versus baseline, significant improvements of intercourse satisfaction (6.8±3.6, 3.9±2.5, p=0.044) and erectile function (17.4±8.9, 7.3±4.5, p=0.006) domains of the International Index of Erectile Function-15 and Erection Hardness Scale (2.6±1.1, 1.3±0.8, p=0.008) were observed in the total population. Spontaneous erections showed significantly greater improvement with the higher doses. Clinical benefits were associated with improvement of peak systolic velocity and of % penile nitric oxide release test and sustained after 1 yr. Our results need to be confirmed by phase 2 clinical trials.

PATIENT SUMMARY:

We report a phase 1/2 pilot clinical trial investigating cell therapy with injection of bone marrow mononucleated cells to treat postradical prostatectomy erectile dysfunction. No serious side effects occurred. Improvements of erectile function and penile vascularization were noted. Further studies are required to confirm these preliminary results.

KEYWORDS:

Bone marrow; Cavernous nerves; Cell therapy; Erectile dysfunction; Radical prostatectomy; Stem cell

PMID:
26439886
DOI:
10.1016/j.eururo.2015.09.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center